

FAES FARMA, S.A. to the **COMISION NACIONAL DEL MERCADO DE VALORES** communicates the following:

INSIDE INFORMATION

Faes Farma licenses bilastine in the United States

1 - Faes Farma S.A. has signed a license agreement for its flagship product bilastine with Hikma Specialty USA INC for the United States of America.

According to the agreement, Hikma will act as Faes Farma's agent in processing the application for registration in the country and will be responsible for the promotion and commercialization after approval.

Under this agreement Faes will receive an upfront payment for a net value of USD 3,5 million, double-digit royalties and milestone payments (approval, launch and sales milestones).

Hikma is currently Faes Farma's licensee for bilastine in 15 countries in the Middle East and Africa. In the United States, with more than 2,000 employees, Hikma has a strong presence in innovative branded drugs as well as in injectables and generics.

With a value of 324 million euros, the United States is the third largest antihistamine market in the world, following Japan (€913 million) and China (€339 million) (IQVIA, 2020).

This agreement represents a new boost to the bilastine business and completes the geography of bilastine licenses to almost all the main territories in the world.

- 2 Faes also reports hereby the recent regulatory approval of bilastine in Australia (6th largest market worldwide, €125 million).
- 3 Finally, it is also reported that an official application for registration in China is expected to be filed at the end of this year or early 2022.

These advances will make bilastine, which achieved a total turnover of €290 million in 2020 (IQVIA, Faes Farma sales + licensees), closer to one of the leading positions in its therapeutic group worldwide, a reflection of the quality of Faes Farma's own research molecule.

About bilastine

Bilastine is the newest second-generation antihistamine for the treatment of seasonal allergic rhinoconjunctivitis and chronic spontaneous urticaria in adults and children. Bilastine exerts its effect as a selective histamine H1 receptor antagonist and it is to be administered once daily. Bilastine's efficacy across clinical trials is comparable to cetirizine and desloratadine with an excellent safety profile and tolerability, showing somnolence rates not different from placebo, which means a non-sedating effect at therapeutic doses. Bilastine has been developed entirely by Faes Farma, S.A. and is currently approved in 121 countries.

About Faes Farma

Faes Farma was established in Bizkaia, Spain, in 1933. Today, Faes Farma remains a Spanish company with a global focus that researches, manufactures and markets pharmaceutical products in over 100 countries worldwide. Faes has offices, R&D and manufacturing facilities in Spain, Portugal and Central America, as well as sales and marketing infrastructure in other Latin American countries and Africa & Middle East region. Faes employs over 1.600 people and achieved a turnover of approximately €380 million in 2020.

For further information about Faes, visit http://www.faesfarma.com

About Hikma

Headquartered in the UK, Hikma is a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and uses its unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. Committed to its customers, and the people they care for, and by thinking creatively and acting practically, Hikma provides them with a broad range of branded and non-branded generic medicines. With over 8,600 employess, Hikma is a leading licensing partner helping bring innovative health technologies to people around the world.

For more information, please visit: www.hikma.com

Greenhill & Co., LLC

Greenhill & Co., LLC acted as advisors for Faes Farma in this agreement